High Exposure of Intravenous Alemtuzumab is Associated with Increased Risk of Adenovirus reactivation in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.

2026

https://researcherprofiles.org/profile/843792959

42918578

Salinas Cisneros G, Avagyan S, Winestone LE, Pauerstein PT, Chu JI, Higham CS, Shimano KA, Kharbanda S, Huang JN, Long-Boyle JR, Dvorak CC